Safety and efficacy of tixagevimab–cilgavimab in prev

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

Related Keywords

Japan , United States , America , , World Health Organization , Drug Administration , Latin America , Clinical Progression Scale , Cox Regression , Coronavirus Disease Covid 19 , Efficacy , Ntibody , Clinical Trial , Coronavirus , Wood , Monoclonal Antibody , Placebo , Espiratory , Cars , Ars Cov 2 , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Yndrome ,